New option available for Alzheimer’s patients as FDA approves expanded drug use

The FDA has approved the expanded use of Auvelity for treating agitation in Alzheimer's disease patients. Auvelity was originally approved for major depressive disorder and has shown efficacy in two randomized trials. The approval represents a significant advancement in treating complications of Alzheimer's disease.